Laura J. Zitella, RN, MS, NP | Authors

ONS: Infection Risk, Prevention, and Management

April 29, 2013

In this interview, Laura Zitella will be discussing challenges and considerations for management and prevention of infection in the oncology setting-in both patients with solid tumors and those with hematologic malignancies.

Preventing Infection in Patients With Cancer

July 09, 2010

Through evidence-based clinical practice, research, and patient teaching, nurses play an important role in addressing infection risk, and in managing infections, in patients with cancer.

Erythropoietin-Stimulating Agents: New Data Yield New Insights

October 01, 2007

In cancer patients, anemia is multifactorial, resulting from cancer treatment, anemia of malignancy, blood loss, impaired production of or response to erythropoietin, and dysregulation of iron metabolism (decreased dietary iron intake, absorption, and utilization). Clinical studies have found that erythropoietin stimulating agents (ESAs) increase hemoglobin (Hb) levels and reduce the need for blood transfusions by 40%, with ESA-treated patients receiving an average of 1 unit less of red blood cells (RBCs) than non-ESA-treated anemic cancer patients.